Active	Status	Sponsor type	Region	Phase	Filter
7 Active 9 Inactive 16 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Romero, Carlos M
NCT05706506: A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)	Completed	4	152	US	Tirzepatide, LY3298176	Eli Lilly and Company	Type 2 Diabetes, Diabetes Mellitus, Type 2	10/23	10/23
Panorama, NCT06809595: A Phase 3 Trial of MM120 for Generalized Anxiety Disorder	Recruiting	3	250	US	Placebo, MM120 (LSD D-Tartrate)	Mind Medicine, Inc.	Generalized Anxiety Disorder	11/26	05/27
VAYHIT1, NCT05653349: Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)	Recruiting	3	225	Europe, Japan, US, RoW	Ianalumab, VAY736, Placebo, Corticosteroids	Novartis Pharmaceuticals	Primary Immune Thrombocytopenia (ITP)	04/26	12/28
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease	Active, not recruiting	3	17004	Europe, Canada, Japan, US, RoW	Inclisiran sodium 300 mg, Placebo	Novartis Pharmaceuticals	Atherosclerotic Cardiovascular Disease	10/27	10/27
Toro, Luis
No trials found
Gonzalez, Roberto A
No trials found
Vera, Sergio
No trials found